0001593968-23-000303.txt : 20230213 0001593968-23-000303.hdr.sgml : 20230213 20230213163618 ACCESSION NUMBER: 0001593968-23-000303 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230209 FILED AS OF DATE: 20230213 DATE AS OF CHANGE: 20230213 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Brannan Stephen K. CENTRAL INDEX KEY: 0001777631 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38958 FILM NUMBER: 23619125 MAIL ADDRESS: STREET 1: C/O KARUNA THERAPEUTICS, INC. STREET 2: 33 ARCH STREET, SUITE 3110 CITY: BOSTON STATE: MA ZIP: 02110 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Karuna Therapeutics, Inc. CENTRAL INDEX KEY: 0001771917 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 270605902 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 99 HIGH STREET STREET 2: 26TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 BUSINESS PHONE: 857-449-2244 MAIL ADDRESS: STREET 1: 99 HIGH STREET STREET 2: 26TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 4 1 primary_01.xml PRIMARY DOCUMENT X0306 4 2023-02-09 0001771917 Karuna Therapeutics, Inc. KRTX 0001777631 Brannan Stephen K. C/O KARUNA THERAPEUTICS, INC. 99 HIGH STREET, 26TH FLOOR BOSTON MA 02110 false true false false Chief Medical Officer Common Stock 2023-02-09 4 M false 5000 5.45 A 20000 D Common Stock 2023-02-09 4 S false 5000 192.37 D 15000 D Common Stock 2023-02-09 4 A false 8650 0 A 23650 D Option (right to buy) 5.45 2023-02-09 4 M false 5000 0 D 2027-06-01 Common Stock 5000 29677 D Option (right to buy) 187.26 2023-02-09 4 A false 17350 0 A 2033-02-08 Common Stock 17350 17350 D The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 8, 2022. Comprised of restricted stock units ("RSUs"), each representing a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest annually in four 25% installments commencing on February 9, 2024, subject to continued service through such dates. This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of March 1, 2017, with additional vesting as to 12.5% of the shares underlying the option award at the end of each six month period thereafter. 25% of this option shall vest on February 9, 2024, and the remaining 75% shall vest in twelve equal three-month installments over the following three years, subject to continued service through such dates. /s/ Troy Ignelzi, Attorney-in-Fact 2023-02-13